Abingdon Health has signed an exclusive agreement with BioSure

Abingdon Health has signed an exclusive agreement with BioSure, where Abingdon will manufacture BioSure’s lateral flow tests in the field of COVID-19.

The lateral flow production facilities at Abingdon’s York and Doncaster sites will be used for the contract manufacturing services.

CEO of Abingdon Health, Chris Yates, stated: “We are delighted to be supporting BioSure and building on our long-term collaboration with the BioSure team. We are committed to supporting the deployment of these much-needed lateral flow test to the UK and international markets.”

CEO of BioSURE, Brigette Bard, stated: “We are thrilled to be continuing to build our portfolio of products with Abingdon. BioSure is committed to delivering British developed tests to the global market and Abingdon are our ideal partner to manufacture our world-leading products.”